

Revision date: 21-Feb-2015 Version: 3.0 Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Dalteparin Sodium Injection

Trade Name: Fragmin; Fragmine; Ligofragmin

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as anticoagulant agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017

1-800-879-3477

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Signal Word: Not required

Other Hazards

No data available

Australian Hazard Classification

(NOHSC):

Note:

Non-Hazardous Substance. Non-Dangerous Goods.

This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous					
Ingredient	CAS Number	EU	EU Classification	GHS	%
_		EINECS/ELINCS		Classification	
		1 !			I

Material Name: Dalteparin Sodium Injection Page 2 of 7
Revision date: 21-Feb-2015 Version: 3.0

torision date. 21 Feb 2010

3. COMPOSITION / INFORMATION ON INGREDIENTS								
Dalteparin Sodium (Heparin Sodium)	9041-08-1	Not Listed	Not Listed	Not Listed	5-12			

Ingredient	CAS Number	EU	EU Classification	GHS	%
		EINECS/ELINCS		Classification	
		List			
Sodium chloride	7647-14-5	231-598-3	Not Listed	Not Listed	*
Water	7732-18-5	231-791-2	Not Listed	Not Listed	*

Dalteparin Sodium (Heparin Sodium)

Registration Number: 01-2119430937-32-0000

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has

been withheld as a trade secret.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Exposure: Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Formation

Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

Products:

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Material Name: Dalteparin Sodium Injection Page 3 of 7
Revision date: 21-Feb-2015 Version: 3.0

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

Collecting: area thoroughly.

Additional Consideration for Non-essential personnel should be evacuated from affected area. Report emergency

Large Spills: situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Sodium chloride

Latvia OEL - TWA 5 mg/m³
Lithuania OEL - TWA 5 mg/m³

Dalteparin Sodium (Heparin Sodium)

Pfizer OEL TWA-8 Hr: 200µg/m³

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Personal Protective Refer to applicable national standards and regulations in the selection and use of personal

Equipment: protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible. **Skin:** Wear protective clothing when working with large quantities.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

Material Name: Dalteparin Sodium Injection Page 4 of 7
Revision date: 21-Feb-2015 Version: 3.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solution Color: Colorless to pale straw-

color

Odor: No data available. Odor Threshold: No data available.

Molecular Weight: Mixture

Solvent Solubility:No data availableWater Solubility:No data availableSolubility:Soluble: WaterpH:5.0-7.5

Melting/Freezing Point (°C):

Boiling Point (°C):

No data available.

No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Sodium chloride No data available

Molecular Formula:

Dalteparin Sodium (Heparin Sodium)

No data available

Water

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):No data availableVapor Pressure (kPa):No data availableVapor Density (g/ml):No data availableRelative Density:No data available

Specific Gravity: 1.04

Viscosity: No data available

Flammablity:

Autoignition Temperature (Solid) (°C):

Flammability (Solids):

Flash Point (Liquid) (°C):

Upper Explosive Limits (Liquid) (% by Vol.):

Lower Explosive Limits (Liquid) (% by Vol.):

No data available
No data available
No data available

Mixture

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

Products:

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Short Term: Mild eye irritant in experimental animals . May produce allergic reactions following skin contact.

Material Name: Dalteparin Sodium Injection Page 5 of 7
Revision date: 21-Feb-2015 Version: 3.0

11. TOXICOLOGICAL INFORMATION

Known Clinical Effects: Clinical use of this drug has caused hemorrhage, gastrointestinal bleeding, increased bleeding

time. Individuals sensitive to this material or other materials in its chemical class may develop

allergic reactions.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium chloride

Rat Oral LD50 3000 mg/kg Mouse Oral LD50 4000 mg/kg

Dalteparin Sodium (Heparin Sodium)

Rat Oral LD 50 > 5000 mg/kg Mouse Oral LD 50 > 5000mg/kg

Mouse Intraperitoneal LD 50 > 2500mg/kg Rat Intraperitoneal LD 50 2500mg/kg Mouse Intravenous LD 50 2800mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Dalteparin Sodium (Heparin Sodium)

Eye Irritation Rabbit Mild

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Dalteparin Sodium (Heparin Sodium)

Fertility and Embryonic Development Rat Subcutaneous 10 mg/kg/day NOAEL Fertility, Fetotoxicity

Embryo / Fetal Development Rat Intravenous 10,000 mg/kg/day LOAEL Fetotoxicity Embryo / Fetal Development Rabbit Intravenous 2,500 mg/kg/day LOAEL Fetotoxicity

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

DALTEDADIN CODUM IN FOTION

Material Name: Dalteparin Sodium Injection Page 6 of 7 Revision date: 21-Feb-2015 Version: 3.0

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

> specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Non-controlled

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Sodium chloride

CERCLA/SARA 313 Emission reporting Not Listed California Proposition 65 Not Listed Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS/ELINCS List** 231-598-3

Water

CERCLA/SARA 313 Emission reporting Not Listed

Material Name: Dalteparin Sodium Injection Page 7 of 7
Revision date: 21-Feb-2015 Version: 3.0

15. REGULATORY INFORMATION

California Proposition 65
Inventory - United States TSCA - Sect. 8(b)
Australia (AICS):

REACH - Annex IV - Exemptions from the

Not Listed
Present
Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

Dalteparin Sodium (Heparin Sodium)

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Standard for the Uniform Scheduling
for Drugs and Poisons:

Not Listed

Not Listed

Present

Present

Schedule 4

EU EINECS/ELINCS List Not Listed

16. OTHER INFORMATION

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on

Ingredients. Updated Section 15 - Regulatory Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 7 - Handling and

Storage. Updated Section 16 - Other Information.

Revision date: 21-Feb-2015

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
